Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Introduction: Elevated plasma D-dimer has been observed in acute phase of subarachnoid hemorrhage (SAH), while a quantitative evaluation for the association between D-dimer level and prognosis of SAH remains lacking. The aim of the meta-analysis was to investigate the potential predictive role of D-dimer for the short-term functional outcome of patients with SAH. Methods: Relevant observational studies were retrieved by search of PubMed, Web of Science, Embase, Wanfang and CNKI. A poor functional was generally defined as the Glasgow Outcome Scale (1~3) or the modified Rankin Scale (≥3). A random-effects model was used to combine the data by incorporating the influence of between-study heterogeneity. Results: Eleven studies involving 3748 patients with SAH were included. Among them, 1131 patients (30.2%) developed poor functional outcome within 6 months. The pooled results showed that a higher plasma D-dimer at admission was associated with a higher risk of poor functional outcome during follow-up (odds ratio per 1 mg/L increment of D-dimer: 1.65, 95% CI: 1.49 to 1.82, p < 0.001; I2 = 0%). Sensitivity analysis by excluding one study at a time showed similar results. Subgroup analyses suggested that the association between D-dimer and poor functional outcome of patients with SAH was not significantly affected by study design, country, mean age, proportion of men, follow-up duration, methods for defining poor outcome, study quality scores, timing of D-dimer measurement, or the publication year. Conclusion: A high plasma D-dimer at admission is associated with a poor short-term functional outcome of patients with SAH.
Introduction: Elevated plasma D-dimer has been observed in acute phase of subarachnoid hemorrhage (SAH), while a quantitative evaluation for the association between D-dimer level and prognosis of SAH remains lacking. The aim of the meta-analysis was to investigate the potential predictive role of D-dimer for the short-term functional outcome of patients with SAH. Methods: Relevant observational studies were retrieved by search of PubMed, Web of Science, Embase, Wanfang and CNKI. A poor functional was generally defined as the Glasgow Outcome Scale (1~3) or the modified Rankin Scale (≥3). A random-effects model was used to combine the data by incorporating the influence of between-study heterogeneity. Results: Eleven studies involving 3748 patients with SAH were included. Among them, 1131 patients (30.2%) developed poor functional outcome within 6 months. The pooled results showed that a higher plasma D-dimer at admission was associated with a higher risk of poor functional outcome during follow-up (odds ratio per 1 mg/L increment of D-dimer: 1.65, 95% CI: 1.49 to 1.82, p < 0.001; I2 = 0%). Sensitivity analysis by excluding one study at a time showed similar results. Subgroup analyses suggested that the association between D-dimer and poor functional outcome of patients with SAH was not significantly affected by study design, country, mean age, proportion of men, follow-up duration, methods for defining poor outcome, study quality scores, timing of D-dimer measurement, or the publication year. Conclusion: A high plasma D-dimer at admission is associated with a poor short-term functional outcome of patients with SAH.
Introduction: This study aims to evaluate the clinical and imaging risk factors for early neurological deterioration (END) and long-term neurological disability in patients with Single subcortical small infarction (SSSI). Methods: We retrospectively included SSSI patients hospitalized. Outcomes were defined as modified Rankin Scale (mRS) score >2 at follow-up and the occurrence of END during hospitalization. Multivariate logistic regression identified independent predictors of END and long-term outcomes. Stepwise regression analysis was used to develop a predictive model for poor outcomes. The predictive performance of risk factors and the model was assessed using receiver operating characteristic (ROC) curves. Results: A total of 289 SSSI patients were included. During hospitalization, 18 patients (6.2%) experienced END, and 29 patients (10%) had neurological disability at a median follow-up of 21.4 (16.7–25.2) months. Multivariate analysis showed the National Institutes of Health Stroke Scale (NIHSS) score (OR 1.438, 95% CI 1.182–1.749, P < 0.001), Total cholesterol (TC) (OR 1.545, 95% CI 1.014–2.355, P = 0.043), neutrophil to High density lipoprotein cholesterol ratio (NHR) (OR 1.371, 95% CI 1.074–1.75, P = 0.011), and neutrophil count (OR 1.333, 95% CI 1.025–1.733, P = 0.032) were independently associated with END. Age (OR 1.083, 95% CI 1.008–1.163, P = 0.029), lesion diameter (OR 1.121, 95% CI 1.001–1.255, P = 0.048), NIHSS (OR 1.685, 95% CI 1.33–2.134, P < 0.001), symptomatic intracranial artery stenosis (OR 6.655, 95% CI 1.618–27.38, P = 0.009), lacune grading (OR 3.644, 95% CI 1.468–9.048, P = 0.005), and The degree of brain atrophy (OR 2.232, 95% CI 1.199–4.154, P = 0.011) were independently associated with neurological disability. The predictive model for END (included NIHSS score and NHR level) and long-term neurological disability (included age, NIHSS score, symptomatic intracranial artery stenosis, number of lacunes, and brain atrophy) showed areas under the ROC curve of 0.836 and 0.926, respectively. Conclusion: High NIHSS, TC, NHR, and neutrophil count are independent risk factors for END. Age, NIHSS, lesion size, symptomatic intracranial artery stenosis, the degree of lacunes and brain atrophy are predictors of neurological disability in SSSI patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.